Methicillin-resistant Staphylococcus aureus

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

Retrieved on: 
Friday, March 15, 2024
Microsoft, PCR, MRSA, Azure, Automation, Urinary tract infection, Knowledge, Research, UTI, Real-time, Methicillin-resistant Staphylococcus aureus, STI, Clinical trial, GMT, USD, Medical device

In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.

Key Points: 
  • In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
  • During the initial stage of document screening, a total of 281 applications were submitted from 47 different countries, demonstrating worldwide interest in the program.
  • The total number of selected awardees is 17, including those who applied for more than one project.
  • The inaugural Open Innovation Program marks the initial step in this endeavor.

Seegene and Springer Nature Announce Awardees for the Open Innovation Program

Retrieved on: 
Friday, March 15, 2024
Microsoft, PCR, MRSA, Azure, Automation, Urinary tract infection, Knowledge, Research, UTI, Real-time, Methicillin-resistant Staphylococcus aureus, STI, Clinical trial, GMT, USD, Medical device

In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.

Key Points: 
  • In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
  • During the initial stage of document screening, a total of 281 applications were submitted from 47 different countries, demonstrating worldwide interest in the program.
  • The total number of selected awardees is 17, including those who applied for more than one project.
  • The inaugural Open Innovation Program marks the initial step in this endeavor.

Cherry Launches Disinfectable Mouse and Keyboard Set for Hygiene-Sensitive Areas at HIMSS

Retrieved on: 
Monday, March 11, 2024
Scroll, CE, Hospital, MRSA, Disinfectant, FCC, USB, MDR, IP68, Peter Hancock (professor), Sleep, Methicillin-resistant Staphylococcus aureus, Computer, University, Cherry, Movement, Hygiene, Tablet, Laboratory, Research, Mouse, Typesetting

The new hygiene desktop is ideal for extensive entry in hospitals, doctors' surgeries, laboratories, other healthcare facilities, where disinfecting devices is mandatory.

Key Points: 
  • The new hygiene desktop is ideal for extensive entry in hospitals, doctors' surgeries, laboratories, other healthcare facilities, where disinfecting devices is mandatory.
  • When cleaning standard office keyboards, (even when internally sealed) contaminated cleaning fluids can potentially leak out of the gaps.
  • It is also possible the functionality could be impaired if liquids seep into the keyboard housing.
  • The Hygiene Desktop 2 is an individually configurable set consisting of the AK-C8112 hygiene keyboard and the AK-PMH3 3-Button Scroll and AK-PMH3 Scroll Sensor hygienic mice.

OCM™ Wound Platform Demonstrates Antibacterial Activity in Porcine Wound Model, Significantly Reducing Methicillin-Resistant Staphylococcus Aureus (MRSA) and Pseudomonas Aeruginosa (PA) Compared to Comparator and Control Groups

Retrieved on: 
Friday, December 8, 2023
Fibroblast, Safety, Immune system, Methicillin-resistant Staphylococcus aureus, Cole, Ulcer, Peptide, Infection, Patient, Skin, Wound healing, Conditional sentence, DPM, Wound, Podiatry, Pseudomonas aeruginosa, Bacteria, MRSA, Burns, Plant defense against herbivory, Biofilm, Debridement, Inflammation, Copper, Silk, Vaccine

"Limiting bacterial growth is a critical therapeutic aim in treating advanced wounds, but complicating factors often prevent success.

Key Points: 
  • "Limiting bacterial growth is a critical therapeutic aim in treating advanced wounds, but complicating factors often prevent success.
  • The current study was designed to evaluate the antimicrobial and wound-healing effects of OCM™ and Omeza® Skin Protectant against a comparator and a control in a porcine wound model.
  • Wounds in all groups were debrided, treated (except negative control), covered with polyurethane dressings, and retreated on days 4 and 8.
  • OCM™ alone and OCM™ plus Omeza® Skin Protectant showed significantly faster formation of new tissue in MRSA USA300-infected wounds compared to the silver dressing and the control group.

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
Efficacy, Staphylococcus, Methicillin-resistant Staphylococcus aureus, Ambrose, Abstract, Treatment, Clinical, Circulatory system, MRSA, Biomedical Advanced Research and Development Authority, BARDA, Enterococcus faecalis, Infection, ASPR, MSSA, IDSA, Isolates, Laboratory, Liolios Xirolivaditis, Staphylococcus aureus, PK/PD models, SAB, ABSSSI, CABP, Bronchopneumonia, Administration for Strategic Preparedness and Response, Streptococcus pneumoniae, Prescription Drug User Fee Act, Duke University School of Medicine, Infectious Diseases Society of America, Randomness, Development, Administration, Safety, Patient, PDUFA, HHS, Pharmaceutical industry, Vaccine, Ceftobiprole, Litherland, Enterococcus, Allschwil, Streptococcus, Bloodstream infections

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.

Key Points: 
  • Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.
  • It also provides results of pharmacokinetic-pharmacodynamic modeling supporting the dosing regimens to treat severe bacterial infections from the successful clinical phase 3 studies.
  • Abstract #1946 – In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020) – L. Duncan, M. Castanheira, J. I.
  • Smart, M. E. Jones, P. G. Ambrose, K. Litherland
    Abstract #2561 – Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies – A. P. Cammarata, K. Litherland, M. C. Safir, S. M. Bhavnani, M. Saulay, J. I.

CORRECTION: Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New England Journal of Medicine

Retrieved on: 
Wednesday, October 11, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, University, CDC, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Nursing home, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

The findings were published on October 10, 2023, in the New England Journal of Medicine.

Key Points: 
  • The findings were published on October 10, 2023, in the New England Journal of Medicine.
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • “Nursing Home Decolonization for Infection and Hospitalization Prevention” published in the New England Journal of Medicine on October 10, 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2215254?query=featured_home

Lundquist Investigator Dr. Loren Miller Is the Lead Author of the “Universal Decolonization” Study Published in the New English Journal of Medicine

Retrieved on: 
Tuesday, October 10, 2023
Chlorhexidine, Infection, Methicillin-resistant Staphylococcus aureus, Nursing, Doctor of Philosophy, The New England Journal of Medicine, Prevalence, Epidemiology, UCI, Hospital, MPH, University of California, Irvine, CDC, University, Agency for Healthcare Research and Quality, University of California, Irvine School of Medicine, Health, Harbor–UCLA Medical Center, AHRQ, MHSA, Fungal infection, Long-term care, MRSA, Povidone-iodine, Houston, Clinical trial, Nose, Institute of Health and Biomedical Innovation, Korea Disease Control and Prevention Agency, Skin, UCI School of Biological Sciences, Urinary tract infection, Enterococcus-1 RNA motif, Bed, Research, NIH, Pharmaceutical industry, MD, Medicine

“The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.

Key Points: 
  • “The cleansing protocol, called universal decolonization, substantially reduced the number of nursing home residents requiring hospitalization due to infection,” said lead author and Lundquist Investigator, Loren Miller, MD, MPH.
  • Dr. Miller is the Chief of Infectious Diseases at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center in Torrance, California.
  • Each year, 3 million healthcare-associated infections (HAIs) such as methicillin-resistant Staphylococcus aureus (MRSA), bloodstream and urinary tract infections occur in U.S. nursing homes.
  • The findings add to a growing body of Dr. Miller’s research that has been funded by NIH, AHRQ, and other federal sources.

Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections

Retrieved on: 
Thursday, October 5, 2023
Patent, Partnership, Klebsiella pneumoniae, Infection, Methicillin-resistant Staphylococcus aureus, Homeland, Homeland security, Innovation, Acinetobacter baumannii, IND, Fungus, National Institute of Allergy and Infectious Diseases, Fungal infection, Hulk, Laboratory, Pseudomonas aeruginosa, Patient, FDA, Mucormycosis, R01, Macrophage, Escherichia coli, Immune system, USC, Bangladesh Technical Education Board, Vancomycin-resistant Enterococcus, ESBL, Korea Disease Control and Prevention Agency, Blood, Enterococcus, Translational medicine, Denise Spellberg, NIH, Vaccine, Pharmaceutical industry, Klebsiella, Science

Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.

Key Points: 
  • Multiple studies in different laboratories have confirmed the vaccine protected against serious infections within 24 hours and lasts for up to 28 days.
  • Early data suggest that a second dose may extend the window to prevent infection.
  • The study was published in Science and Translational Medicine.
  • These infections are often caused by highly antibiotic-resistant superbugs, many of which are targeted by this new ExBaq vaccine.

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Retrieved on: 
Thursday, September 28, 2023
SAB, ASPR, Staphylococcus, The New England Journal of Medicine, US Foods, Biomedical Advanced Research and Development Authority, Microbiology, MSSA, HHS, Clostridioides, Daptomycin, Overalls, Infection, Survival, MRSA, Administration for Strategic Preparedness and Response, Duke University School of Medicine, Associate, Staphylococcus aureus, Ceftobiprole, NEJM, ABSSSI, Clostridioides difficile infection, Administration, Development, Patient, Fungal infection, Disease, Mortality, Bacteria, BARDA, Food, Methicillin-resistant Staphylococcus aureus, New Drug Application, Pharmaceutical industry, Vaccine, Allschwil, Medicine

ERADICATE is the largest registrational study for SAB conducted to date and ceftobiprole showed similar clinical benefit compared to daptomycin, which is a standard of care antibiotic in the treatment of SAB.

Key Points: 
  • ERADICATE is the largest registrational study for SAB conducted to date and ceftobiprole showed similar clinical benefit compared to daptomycin, which is a standard of care antibiotic in the treatment of SAB.
  • Using a pre-defined non-inferiority margin of 15%, treatment with ceftobiprole was non-inferior to daptomycin with overall treatment success achieved in 69.8% of patients in the ceftobiprole group compared to 68.7% in the daptomycin group.
  • The results for the primary study outcome were consistent in key subgroups, including patients with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA).
  • Ceftobiprole was generally well tolerated and showed a safety profile consistent with previous phase 3 studies and the post-marketing experience.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

Retrieved on: 
Friday, September 22, 2023
Priority review, Food and Drug Administration Safety and Innovation Act, Innovation Act, IV, Prevalence, Amputation, Diabetes, QIDP, Methicillin, S. aureus, Methicillin-resistant Staphylococcus aureus, Infection, Act, MRSA, NDA, Fast Track, Osteomyelitis, ABSSSI, GAIN, Diabetic foot infection, Patient, Ulcer, Disease, DFI, Mortality, Toxic shock syndrome, Bacteria, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-positive bacteria, Food, Pharmaceutical industry, FDASIA

Oral contezolid and intravenous (IV) contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with DFI.

Key Points: 
  • Oral contezolid and intravenous (IV) contezolid acefosamil are currently being studied in a global Phase 3 clinical trial in treatment of patients with DFI.
  • Both products were previously granted QIDP designation and Fast Track status in 2018 for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
  • With excellent microbiological activity against common Gram-positive bacteria, contezolid and contezolid acefosamil are well positioned to benefit DFI patients, particularly due to methicillin-resistant Staphylococcus aureus (MRSA).
  • "We believe that MicuRx can offer an important new choice for DFI treatment with flexibility of oral and IV formulations."